###begin article-title 0
c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: JW JR. Performed the experiments: JW HW ZL QW JDL. Analyzed the data: JW ABH JR. Contributed reagents/materials/analysis tools: REM. Wrote the paper: JW ABH JR.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Malignant gliomas rank among the most lethal cancers. Gliomas display a striking cellular heterogeneity with a hierarchy of differentiation states. Recent studies support the existence of cancer stem cells in gliomas that are functionally defined by their capacity for extensive self-renewal and formation of secondary tumors that phenocopy the original tumors. As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 708 709 708 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 711 712 711 712 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 937 945 937 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1015 1019 <span type="species:ncbi:10090">mice</span>
Based on previous methods that we and others have employed, tumor cell populations were enriched or depleted for cancer stem cells using the stem cell marker CD133 (Prominin-1). We characterized c-Myc expression in matched tumor cell populations using real time PCR, immunoblotting, immunofluorescence and flow cytometry. Here we report that c-Myc is highly expressed in glioma cancer stem cells relative to non-stem glioma cells. To interrogate the significance of c-Myc expression in glioma cancer stem cells, we targeted its expression using lentivirally transduced short hairpin RNA (shRNA). Knockdown of c-Myc in glioma cancer stem cells reduced proliferation with concomitant cell cycle arrest in the G0/G1 phase and increased apoptosis. Non-stem glioma cells displayed limited dependence on c-Myc expression for survival and proliferation. Further, glioma cancer stem cells with decreased c-Myc levels failed to form neurospheres in vitro or tumors when xenotransplanted into the brains of immunocompromised mice.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
These findings support a central role of c-Myc in regulating proliferation and survival of glioma cancer stem cells. Targeting core stem cell pathways may offer improved therapeutic approaches for advanced cancers.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 414 417 414 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Jin1">[1]</xref>
###xml 419 422 419 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Ito1">[2]</xref>
###xml 501 504 501 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao1">[3]</xref>
###xml 517 520 517 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Hermann1">[4]</xref>
###xml 570 573 570 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao1">[3]</xref>
###xml 575 578 575 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Li1">[5]</xref>
###xml 580 583 580 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Zhang1">[6]</xref>
###xml 585 588 585 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Liu1">[7]</xref>
###xml 590 593 590 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Todaro1">[8]</xref>
###xml 595 598 595 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao2">[9]</xref>
The emerging cancer stem cell model suggests that tumors are organized in a hierarchy with a subpopulation of cancer stem cells responsible for tumor maintenance and progression. Cancer stem cells are highly tumorigenic and phenocopy the original tumors in rodent xenograft models. Depletion of the cancer stem cell population greatly impairs the potential to initiate xenograft tumor formation of the bulk tumors [1], [2]. The cancer stem cell population also contributes to solid tumor angiogenesis [3], metastasis [4], and resistance to chemotherapy and radiotherapy [3], [5], [6], [7], [8], [9]. While this model has been validated in a growing list of haematopoietic and solid tumors, the molecular signaling pathways orchestrating the biology of cancer stem cells remain to be elucidated.
###end p 9
###begin p 10
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Vita1">[10]</xref>
###xml 408 412 408 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Murphy1">[11]</xref>
###xml 589 593 589 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Wong1">[12]</xref>
###xml 736 740 736 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Wong1">[12]</xref>
###xml 905 909 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Takahashi1">[13]</xref>
###xml 1056 1060 1056 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Takahashi1">[13]</xref>
###xml 1062 1066 1062 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Nakagawa1">[14]</xref>
###xml 1068 1072 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Knoepfler1">[15]</xref>
###xml 1074 1078 1074 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Takahashi2">[16]</xref>
###xml 1366 1370 1366 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Wilson1">[17]</xref>
###xml 1714 1718 1714 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Waikel1">[18]</xref>
###xml 1720 1724 1720 1724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Gandarillas1">[19]</xref>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 635 640 <span type="species:ncbi:9606">human</span>
###xml 1272 1277 <span type="species:ncbi:10090">mouse</span>
###xml 1638 1643 <span type="species:ncbi:9606">human</span>
The c-Myc oncoprotein has been extensively studied for its instrumental role in proliferation and growth of normal and neoplastic cells. Deregulated c-Myc is found in diverse human tumors and is often associated with advanced malignancy and poor prognosis [10]. As c-Myc has been recently recognized as an important regulator of stem cell biology, it may serve as a link connecting malignancy and "stemness" [11]. In either normal or transformed cells, c-Myc alone activates an embryonic stem cell-like transcriptional module, which strongly correlates with tumor metastasis and mortality [12]. Ectopic c-Myc expression in transformed human keratinocytes dramatically increases the cancer stem cell fraction and enhances tumorigenicity [12]. Introduction of c-Myc with other transcription factors (including Oct3/4, Sox2, and Klf4) generates induced pluripotent stem (iPS) cells from differentiated cells [13]. Excluding c-Myc from this combination without eliminating endogenous c-Myc expression, drastically reduces the efficiency of iPS cell production [13], [14], [15], [16]. While all of these data suggest a role for c-Myc in maintaining stem cells, other functions of c-Myc in regulating stem cell biology have also been described. Conditional knockout of c-Myc in mouse bone marrow does not prevent proliferation or self-renewal of haematopoietic stem cells [17]. It rather results in accumulation of haematopoietic stem cells in bone marrow, suggesting that c-Myc specifically controls the interaction between haematopoietic stem cells and their niches. Additionally, over-expression of c-Myc-estrogen receptor fusion protein in human epidermal stem cells drives differentiation rather than proliferation [18], [19].
###end p 10
###begin p 11
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Louis1">[20]</xref>
###xml 442 446 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Herms1">[21]</xref>
###xml 619 623 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Jensen1">[22]</xref>
###xml 781 785 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Jensen1">[22]</xref>
###xml 138 143 <span type="species:ncbi:9606">human</span>
###xml 349 354 <span type="species:ncbi:9606">human</span>
###xml 544 549 <span type="species:ncbi:10090">mouse</span>
###xml 589 594 <span type="species:ncbi:9606">human</span>
###xml 633 638 <span type="species:ncbi:10090">mouse</span>
Because of the recognized functions of c-Myc in both normal stem cell biology and neural malignancy, we investigated the role of c-Myc in human glioma cancer stem cells. Gliomas are the most common primary intrinsic tumor type of the central nervous system. High grade gliomas (World Health Organization grades III and IV) are among the most lethal human malignancies [20]. In glioma, c-Myc expression correlates with the grade of malignancy [21]. Expression of c-Myc driven by the glial fibrillary acidic protein (GFAP)-promoter in developing mouse astroglia induces tumors that resemble human glioblastoma multiforme [22]. In this mouse model, the tumor mass contains fast dividing subpopulation that express c-Myc and relatively quiescent tumor cells that lack c-Myc expression [22]. We have now determined that the glioma cancer stem cells expressed higher levels of c-Myc relative to matched non-stem tumor cells and the activity of c-Myc is required for proliferation, growth, and survival of glioma cancer stem cells. Loss of c-Myc abolished xenograft formation by glioma cancer stem cells, underscoring a key role of c-Myc in glioma cancer stem cell maintenance.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Glioma cancer stem cells express high levels of c-Myc
###end title 13
###begin p 14
###xml 332 335 332 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao2">[9]</xref>
###xml 467 476 467 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g001">Figure 1A</xref>
###xml 605 614 605 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g001">Figure 1B</xref>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao3">[23]</xref>
###xml 653 657 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Ligon1">[24]</xref>
###xml 786 795 786 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g001">Figure 1B</xref>
###xml 1035 1043 1035 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1053 1062 1053 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g001">Figure 1C</xref>
###xml 1198 1207 1198 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g001">Figure 1D</xref>
###xml 1602 1611 1602 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g001">Figure 1E</xref>
###xml 229 234 <span type="species:ncbi:9606">human</span>
###xml 845 850 <span type="species:ncbi:9606">human</span>
###xml 995 1000 <span type="species:ncbi:9606">human</span>
###xml 1320 1325 <span type="species:ncbi:9606">human</span>
To investigate the biological functions of c-Myc in regulation of glioma cancer stem cells, we first determined expression of c-Myc in these cells. Short term cultures enriched or depleted for cancer stem cells were derived from human brain tumor specimens using CD133 selection and characterized as we have previously demonstrated [9]. Quantitative real-time PCR revealed that CD133+ glioma cells expressed higher c-Myc mRNA levels than matched CD133- glioma cells (Figure 1A). The differential mRNA levels translated into higher levels of c-Myc protein in CD133+ glioma cells than matched CD133- cells (Figure 1B). Consistent with prior reports [23], [24], the cancer stem cell-enriched fractions also expressed high levels of Olig2, a marker of adult neural multipotent progenitors (Figure 1B). To directly measure the expression of c-Myc in human brain tumors, we further evaluated c-Myc expression by flow cytometry in both CD133+ and CD133- fractions of glioma cells acutely isolated from human surgical biopsy specimens without in vitro culture (Figure 1C). Approximately half of the CD133+ cells were high in c-Myc expression, whereas nearly 90% CD133- cells expressed low levels of c-Myc (Figure 1D). We further examined c-Myc expression in glioma cancer stem cells using sections generated from acutely frozen human glioma surgical specimens. Because co-staining with CD133 was not compatible with antigen retrieval method required for c-Myc staining, we co-stained c-Myc with another neural stem cell marker Nestin. Greater than 90% of Nestin positive glioma cells were also c-Myc positive (Figure 1E). These data suggest that c-Myc is highly expressed in glioma cancer stem cells.
###end p 14
###begin title 15
c-Myc is highly expressed in glioma cancer stem cells.
###end title 15
###begin p 16
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 729 734 <span type="species:ncbi:9606">human</span>
###xml 1071 1076 <span type="species:ncbi:9606">human</span>
(A) CD133- and CD133+ cells were isolated from glioma surgical biopsy specimens passaged short-term in immunocompromised mice and briefly cultured. Total RNA was isolated from both CD133- and CD133+ cells. cDNA was prepared by reverse transcription. Expression of c-Myc was then determined by quantitative real-time PCR and normalized to beta-actin and HPRT1. Relative mRNA levels of c-Myc in CD133- cells were assigned a value of 1. Data are represented as mean+/-S.E.M in this and all subsequent graphs (#: p<0.001). (B) Total cellular lysates were resolved by SDS-PAGE. Protein levels of c-Myc and Olig2 were determined by immunoblotting. Actin was blotted as the loading control. (C) Glioma cells were isolated directly from human surgical biopsy specimens, fixed in 4% paraformaldehyde following dissociation, labeled with anti-CD133-APC and anti-c-Myc-FITC, and subjected to FACS analysis. (D) Percentage of cells expressing high levels of c-Myc within either the CD133- fraction or the CD133+ fraction was demonstrated (#: p<0.001). (E) Sections of freshly frozen human glioma surgical biopsy specimens were fixed and co-stained for c-Myc (green) and Nestin (red). Nuclei were counterstained with Hoechst 33342. Representative images (630x) were demonstrated.
###end p 16
###begin title 17
c-Myc regulates cell cycle progression and proliferation of glioma cancer stem cells
###end title 17
###begin p 18
###xml 446 462 446 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g002">Figure 2A and 2B</xref>
###xml 646 647 646 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 649 650 649 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 693 701 693 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g003">Figure 3</xref>
###xml 831 839 831 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g003">Figure 3</xref>
###xml 1133 1134 1133 1134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1137 1138 1137 1138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1153 1162 1153 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 1162 1166 1162 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Dang1">[26]</xref>
###xml 1168 1172 1168 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bouchard1">[27]</xref>
###xml 1235 1236 1235 1236 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1270 1271 1270 1271 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1295 1304 1295 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g002">Figure 2B</xref>
###xml 1324 1333 1324 1333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 1455 1464 1455 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g002">Figure 2B</xref>
###xml 1530 1531 1530 1531 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1539 1548 1539 1548 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 1705 1706 1705 1706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1714 1723 1714 1723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 1847 1848 1847 1848 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1927 1928 1927 1928 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2002 2003 2002 2003 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 2022 2023 2022 2023 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2051 2052 2051 2052 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 2263 2264 2263 2264 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 2272 2281 2272 2281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
c-Myc plays a key role in regulating cellular proliferation by controlling the expression of cell cycle proteins. To interrogate the role of c-Myc in the cell cycle of glioma cancer stem cells, we targeted c-Myc expression by infection with lentivirus expressing shRNA specific to c-Myc. Two different shRNAs efficiently decreased c-Myc expression in both CD133- and CD133+ glioma cells as shown by quantitative real-time PCR and immunoblotting (Figure 2A and 2B). Similar results were found in another tumor specimen (T4597, data not shown). Depletion of c-Myc significantly reduced the S phase cell population with concomitant increase of the G0/G1 cell population in CD133+ cells (p<0.001, Figure 3). In contrast, CD133- cells displayed a lower rate of proliferation with a smaller S phase population than matched CD133+ cells (Figure 3 and data not shown), and the cell cycle progression in CD133- cells was not significantly altered by knockdown of c-Myc. Regulation of the cell cycle by c-Myc is commonly mediated through transcriptional regulation of the cyclins and the cyclin-dependent kinase inhibitors, including cyclins D1, D2, and E and p21WAF1/CIP1[26], [27] (). Attenuating c-Myc expression specifically reduced cyclin D1 protein levels, but not cyclins D2 or E, in CD133+ cells (Figure 2B). Additionally, p21WAF1/CIP1 protein levels were upregulated in cancer stem cells depleted of c-Myc, whereas p53 levels were only moderately altered (Figure 2B). Quantitative real-time PCR showed a similar pattern of cyclin D1 and p21WAF1/CIP1 regulation at mRNA levels by c-Myc in CD133+ cells, suggesting c-Myc regulated these two genes at the level of transcription. In striking contrast, cyclin D1 and p21WAF1/CIP1 were minimally altered by knocking down c-Myc at either the mRNA or protein levels in CD133- cells. Notably, basal cyclin D1 levels were higher in CD133+ cells than matched CD133- cells, whereas cyclin D2 and cyclin E levels were higher in CD133- cells, suggesting that cyclin D1, but not cyclins D2 or E, is critical for the G1/S transition in CD133+ glioma cells. Taken together, these results suggest that c-Myc regulates cell cycle progression in glioma cancer stem cells, at least partially, through controlling expression of cyclin D1 and p21WAF1/CIP1.
###end p 18
###begin title 19
c-Myc modulates cell cycle regulators of glioma cancer stem cells.
###end title 19
###begin p 20
###xml 221 230 221 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 240 241 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 262 263 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 384 385 384 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 395 396 395 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 414 423 414 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
(A) Early passage (<P5) T3359 glioblastoma CD133- or CD133+ cells were infected by lentivirus directing expression of either non-targeting shRNA (NT) or c-Myc specific shRNAs (sh-1 and sh-2). The mRNA levels of c-Myc, p21WAF1/CIP1, cyclin D1 (cycD1) and cyclin D2 (cycD2) were determined by quantitative real-time PCR 3 days after infection. (B) Protein levels of c-Myc, p53, cyclin D1, cyclin D2, cyclin E and p21WAF1/CIP1 were determined by immunoblotting.
###end p 20
###begin title 21
c-Myc induces cell cycle arrest of glioma cancer stem cells.
###end title 21
###begin p 22
###xml 593 594 589 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 606 607 602 603 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 609 610 605 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
(A, B) Early passage (<P5) T3359 glioblastoma CD133- or CD133+ cells were infected by lentivirus directing expression of either non-targeting shRNA (NT) or c-Myc specific shRNAs (sh-1 and sh-2). Three days after infection, cells were fixed in 75% ethanol and labeled with 10 microg/ml propidium iodide. Cell cycle distribution was determined by flow cytometry. (A) Data were generated from three independent experiments. *, p<0.05; #, p<0.001 with one-way ANOVA comparison of the control groups to the corresponding c-Myc knockdown groups. (B) Representitive FACS plots are displayed. M1-sub G0 phase; M2-G0/G1 phase; M3-S phase; M4-G2/M phase.
###end p 22
###begin p 23
###xml 132 140 132 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Singh1">[28]</xref>
###xml 146 150 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Singh2">[29]</xref>
###xml 652 660 652 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g004">Figure 4</xref>
###xml 760 768 760 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g004">Figure 4</xref>
###xml 72 77 <span type="species:ncbi:9606">human</span>
Previous reports demonstrated that brain tumor stem cells isolated from human surgical biopsy specimens were actively proliferative in vitro[28], [29], but the numbers of matched CD133- tumor cells barely increased after a week of culture. Our data that the relatively high expression of c-Myc in glioma cancer stem cells is essential for their cell cycle regulation suggest that the growth of these cells may also require c-Myc activity. As demonstrated by growth curve assays, the total number of control CD133+ cells increased roughly six or seven fold over five days, whereas CD133+ cells depleted of c-Myc did not increase or decreased in number (Figure 4). Conversely, growth of the CD133- population was only moderately attenuated with c-Myc knockdown (Figure 4). These results suggest that c-Myc preferentially contributes to sustained growth of tumor initiating cells.
###end p 23
###begin title 24
Depletion of c-Myc inhibits growth of glioma cancer stem cells.
###end title 24
###begin p 25
(A) T3359, (B) T3832, and (C) T4597 CD133- and CD133+ cells were isolated and infected as described. Cells were then plated in 96-well plates in triplicate at 5000 cells per well for CD133- cells or 1000 cells per well for CD133+ cells. Total viable cell numbers were then determined by the CellTiter-Glo Luminescent Cell Viability Assay (Promega) daily. *, p<0.05; #, p<0.001 with one-way ANOVA comparison of the control groups to the corresponding c-Myc knockdown groups on the same day.
###end p 25
###begin title 26
Loss of c-Myc induces apoptosis in glioma cancer stem cells
###end title 26
###begin p 27
###xml 747 751 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Kaptein1">[30]</xref>
###xml 753 757 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Thompson1">[31]</xref>
###xml 759 763 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Huang1">[32]</xref>
###xml 765 769 765 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Prendergast1">[33]</xref>
###xml 1105 1117 1105 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g005">Figure 5A, C</xref>
###xml 1376 1388 1376 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g005">Figure 5B, D</xref>
c-Myc regulates not only cellular proliferation but also cellular survival. In concordance with a role in survival, we noted an accumulation of dead cells in the CD133+ fraction depleted of c-Myc expression during the growth curve experiments that was not present in controls (data not shown). Conversely, indications of cell death were limited in matched CD133- cells, regardless of c-Myc status, suggesting that loss of c-Myc might specifically induce apoptosis in CD133+ cells. The role of c-Myc in regulating apoptosis remains controversial. Previous reports have demonstrated that c-Myc promotes apoptosis in cancer cell lines and various normal cell types, whereas downregulation of c-Myc also leads to apoptosis under certain circumstances [30], [31], [32], [33]. To distinguish the anti-apoptotic or pro-apoptotic role of c-Myc in glioma cancer stem cells, we quantified apoptotic cell populations following knockdown of c-Myc. Annexin V staining revealed that depletion of c-Myc induced apoptosis in CD133+ glioma cells, whereas the control CD133+ cells contained a minimal apoptotic population (Figure 5A, C). In contrast, the CD133- population had only background staining of Annexin V regardless of c-Myc levels. Consistent with these data, the combined caspase 3/7 activity was elevated in CD133+ cells following c-Myc knockdown, but not in matched CD133- cells (Figure 5B, D). Taken together, these data suggest that c-Myc is a survival factor for glioma cancer stem cells.
###end p 27
###begin title 28
Depletion of c-Myc induces apoptosis in glioma cancer stem cells.
###end title 28
###begin p 29
###xml 783 791 783 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g004">Figure 4</xref>
(A, B) T3359 and (C, D) T4597 CD133- and CD133+ cells were isolated and infected as described. (A, C) Six days after infection, cells were trypsinized and quantified for apoptosis using the Annexin V-FITC Apoptosis Detection kit (Calbiochem). The percentage of FITC positive cells was determined by FACS analysis, and dead cells were excluded by propidium iodide staining. (B, D) These cells were also plated in 96-well plates at 5000 cells per well for CD133- cells and 1000 cells per well for CD133+ cells after infection and selection. Six days after infection, combined activities of caspase 3 and caspase 7 were determined by the Caspase 3/7 Luminescence Assay kit (Promega), and were normalized by the viable cell numbers determined by the CellTiter-Glo assays as described in Figure 4. *, p<0.05 with one-way ANOVA comparison of the control groups to the corresponding c-Myc knockdown groups.
###end p 29
###begin title 30
Loss of c-Myc impairs neurosphere formation by glioma cancer stem cells
###end title 30
###begin p 31
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Jensen2">[34]</xref>
###xml 376 379 376 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao2">[9]</xref>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Singh1">[28]</xref>
###xml 556 565 556 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g006">Figure 6A</xref>
###xml 722 731 722 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g006">Figure 6B</xref>
###xml 1113 1122 1113 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g006">Figure 6C</xref>
Sharing certain key characteristics of normal stem cells, cancer stem cells are capable of self-renewal, which allows sustained maintenance of this subpopulation and expansion of the whole tumor. Serial neurosphere formation assay has been utilized as a surrogate of the self-renewal capacity of neural stem cells [34], and was recently employed in the brain tumor stem cells [9], [28]. In primary neurosphere formation assays, approximately 15% of control CD133+ cells formed neurospheres, whereas very few spheres were formed by cells depleted of c-Myc (Figure 6A). Neurospheres developed in 100% of wells in the control group when plated at a density of 100 cells/well and in 80-85% wells when plated at 10 cells/well (Figure 6B). In contrast, neurospheres were formed by cells depleted of c-Myc expression in only 10% (shRNA-1) or 30% (shRNA-2) of wells when plated at a density of 100 cells/well, while no spheres were found when these cells were plated at 10 cells/well. Of note, neurospheres formed by cells with reduced c-Myc expression were markedly smaller than the spheres formed by the control cells (Figure 6C) and merely met the minimal criteria to be scored in our experiments. Lack of neurospheres formed by glioma cancer stem cells depleted of c-Myc suggests impaired self-renewal. However, assessing secondary neurosphere formation was precluded because very few spheres were generated in the knockdown groups in the primary assay and the neurospheres had limited viability. These studies therefore could not definitely determine if c-Myc expression is required for self-renewal of glioma cancer stem cells. However, it is expected that self-renewal of glioma cancer stem cells is inhibited by knockdown of c-Myc, based on our observations that glioma cancer stem cells failed to proliferate and underwent apoptosis upon knockdown of c-Myc.
###end p 31
###begin title 32
Depletion of c-Myc attenuates neurosphere formation by glioma cancer stem cells.
###end title 32
###begin p 33
(A) T3359 CD133+ cells were infected with lentivirus and selected as described. Cells were then plated at 100 or 10 cells per well in 24-well plates in the presence of 1 microg/ml puromycin. Eight wells were plated for each group. The numbers of neurospheres in each well were determined in seven days. Spheres that contained more than 20 cells were scored. (B) Percentage of wells without neurospheres formed was quantified. #, p<0.001 with one-way ANOVA comparison of the control groups to the corresponding c-Myc knockdown groups. (C) Representative photographs of neurospheres formed by cells expressing non-targeting shRNA or c-Myc specific shRNA (bars = 50 microm). (D, E) Similar results were demonstrated in T4302 CD133+ cells.
###end p 33
###begin title 34
Knockdown of c-Myc inhibits the tumorigenic potential of glioma cancer stem cells
###end title 34
###begin p 35
###xml 765 773 765 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g007">Figure 7</xref>
###xml 927 935 927 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g007">Figure 7</xref>
###xml 404 409 <span type="species:ncbi:10090">mouse</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 792 796 <span type="species:ncbi:10090">mice</span>
Based on the requirement of c-Myc activity for cell cycle progression, growth and survival, of CD133+ glioma cells in culture, we examined the role of c-Myc expression in their tumorigenic potential. CD133+ glioma cells were infected with non-targeting control lentivirus or lentivirus expressing c-Myc shRNA. Following puromycin selection, 5000 cells of each group were injected into the brains of nude mouse in quadruplicate. 100% of mice bearing control cells rapidly developed neurologic signs and displayed large tumors on histopathology composed of pleomorphic cells featuring high nuclear to cytoplasmic ratios, prominent nucleoli with minimal cytoplasm, brisk mitotic activity and central geographic necrosis, consistent with a high grade glial malignancy (Figure 7). In contrast, no mice injected with cells depleted of c-Myc expression developed signs and after 100 days demonstrated no evidence of neoplastic cells (Figure 7). Thus, c-Myc appears to be essential for cancer stem cells to form tumors.
###end p 35
###begin title 36
c-Myc knockdown abolishes xenograft tumor formation by glioma cancer stem cells.
###end title 36
###begin p 37
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 158 163 <span type="species:ncbi:10090">mouse</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 206 210 <span type="species:ncbi:10090">Mice</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 1343 1348 <span type="species:ncbi:10090">Mouse</span>
(A) T3359 CD133+ cells were infected and selected as described. After selection, cells were injected into brains of athymic BALB/c nu/nu mice (5000 cells per mouse). Four mice were injected for each group. Mice in the control group were sacrificed upon the development of neurologic signs. All the mice bearing c-Myc knockdown glioma cells did not develop neurologic signs and were sacrificed after 100 days without evidence of tumor. Kaplan-Meier survival curves are displayed. (B) Representative photographs of hematoxylin and eosin staining of intracranial xenograft tumors (10x). (C) Xenograft tissue of the control group composed of pleomorphic cells featuring high nuclear to cytoplasmic ratios, prominent nucleoli with minimal cytoplasm, brisk mitotic activity and central geographic necrosis (asterisk, 600x). (D) The control glioma xenograft exhibited focal areas of better differentiated tumor cells with relatively more eosinophilic cytoplasm and cells with eccentric cytoplasmic profiles suggestive of a gemistocytic appearance (arrows, 400x). (E) Xenograft tumor of the control group exhibits infiltration of tumor cells into the surrounding brain tissue along the margin. The mitotically active (arrowhead) infiltrating tumor cells exhibit high nuclear to cytoplasmic ratios and elongated fibrillar cytoplasm (arrow) (600x). (F) Mouse brain injected with T3359 cells expressing c-Myc shRNA showed no evidence of tumor at the needle injection site (arrows, 200x).
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Lapidot1">[35]</xref>
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bonnet1">[36]</xref>
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Singh1">[28]</xref>
###xml 343 347 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Singh2">[29]</xref>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-AlHajj1">[37]</xref>
###xml 373 377 373 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-RicciVitiani1">[38]</xref>
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-OBrien1">[39]</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Li2">[40]</xref>
###xml 428 432 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Prince1">[41]</xref>
###xml 877 878 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 899 902 899 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao2">[9]</xref>
###xml 1273 1282 1273 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g001">Figure 1D</xref>
###xml 1416 1425 1416 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g001">Figure 1E</xref>
###xml 1534 1558 1534 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g002">Figure 2B, lanes 5 and 6</xref>
###xml 1653 1670 1653 1670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g002">Figure 2B, lane 1</xref>
###xml 1994 1998 1994 1998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Shachaf1">[42]</xref>
###xml 854 863 <span type="species:ncbi:10090">nude mice</span>
###xml 1155 1160 <span type="species:ncbi:9606">human</span>
###xml 1375 1380 <span type="species:ncbi:9606">human</span>
###xml 1832 1837 <span type="species:ncbi:10090">mouse</span>
The cancer stem cell hypothesis has engendered significant controversy, but the presence of heterogeneity of tumor cells in some cancers is well recognized. Tumor cells that display stem cell-like characteristics and initiate xenograft tumors have been purified from an increasing number of cancers, including leukemia [35], [36], brain [28], [29], breast [37], colorectal [38], [39], pancreatic [40], and head and neck cancers [41]. These cancer stem cells are functionally defined through assays of self-renewal and serial xenotransplantation assays in rodent models. Experiments demonstrate that the tumorigenic potential of cancer stem cells is at least several magnitudes higher than the bulk tumors. For example, glioma cancer stem cells enriched by selection of the CD133 surface antigen form orthotopic xenograft tumors with 500 cells in athymic nude mice, whereas 2x106 CD133- cells cannot [9]. In line with the potent tumorigenicity of brain tumor stem cells, we demonstrated here that CD133+ glioma cancer stem cells highly expressed the c-Myc oncoprotein. FACS analysis demonstrated that at least half of CD133+ cells acutely dissociated from human surgical biopsy specimens had high levels of c-Myc, whereas the majority (>85%) of CD133- cells were c-Myc-low (Figure 1D). Similar co-expression of c-Myc and a stem cell marker, Nestin, was identified directly on human surgical biopsy specimen sections (Figure 1E). Notably, glioma cancer stem cells expressing c-Myc shRNA still retained residual levels of c-Myc protein (Figure 2B, lanes 5 and 6) that were higher than the c-Myc levels found in CD133- cells expressing non-targeting shRNA (Figure 2B, lane 1). Nonetheless, the reduced levels of c-Myc were incapable of supporting proliferation, growth, survival, and tumorigenesis of glioma cancer stem cells. A recent mouse model of T-cell lymphoma using conditionally expressed c-Myc also suggest that certain threshold level of c-Myc is required to maintain the tumor phenotype [42]. Collectively, our results highlight a necessary requirement of high c-Myc expression in glioma cancer stem cells.
###end p 39
###begin p 40
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Dalerba1">[43]</xref>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Ishikawa1">[44]</xref>
###xml 821 829 821 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Singh1">[28]</xref>
###xml 895 899 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Singh2">[29]</xref>
###xml 1052 1056 1052 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Langenau1">[45]</xref>
###xml 1186 1194 1186 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1222 1231 1222 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g003">Figures 3</xref>
###xml 1236 1237 1236 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g004">4</xref>
###xml 1571 1575 1571 1575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Dang1">[26]</xref>
###xml 1577 1581 1577 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Zeller1">[46]</xref>
###xml 1616 1617 1616 1617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1617 1621 1617 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Daksis1">[47]</xref>
###xml 1647 1656 1647 1656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 1691 1695 1691 1695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Gartel1">[48]</xref>
###xml 1697 1701 1697 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Mitchell1">[49]</xref>
###xml 1787 1796 1787 1796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 1809 1810 1809 1810 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 360 365 <span type="species:ncbi:9606">human</span>
###xml 857 862 <span type="species:ncbi:9606">human</span>
###xml 1015 1024 <span type="species:ncbi:7955">zebrafish</span>
Cancer stem cells have been proposed as slowly cycling cells, like their somatic stem cell counterparts [43]. Rapid expansion of tumors is then dependent on the fast dividing progenitor cells. The slow cell cycle may provide cancer stem cells a protective mechanism against certain therapeutic approaches that target rapid proliferating cells. For example, in human acute myelogenous leukemia, the quiescent leukemia stem cells are resistant to chemo-drugs that dependent on cell cycle [44]. Nevertheless, characteristics of cancer stem cells may not be necessarily uniform across different cancer types, and the biology of cancer stem cells may change throughout different stages of tumor development. In brain tumors, Singh and co-workers first demonstrated that only the CD133+ cancer stem cell population proliferate in vitro when acutely isolated from human surgical biopsy specimens [28], [29]. These results were similar to the highly proliferative cancer stem cells that were characterized in a RAS-induced zebrafish embryonal rhabdomyosarcoma [45]. In the present study, we determined that the CD133+ glioma cells contained a higher percentage of S phase cells and grew faster in vitro than matched CD133- cells (Figures 3 and 4). We also found that proliferation and growth of glioma cancer stem cells were severely impaired upon knockdown of c-Myc, but importantly, the cell cycle progression of CD133- glioma cells were relatively insensitive to loss of c-Myc. The transcriptional programs regulated by c-Myc remain poorly defined and dependent on cell state [26], [46], but include induction of cyclin D1[47] and repression of the p21WAF1/CIP1 cyclin-dependent kinase inhibitor [48], [49]. Consistently, expression of cell cycle regulators downstream of c-Myc, including p21WAF1/CIP1 and cyclin D1, was altered in glioma cancer stem cells following c-Myc knockdown, but not in the CD133- cells. These data uncover a specific role of c-Myc and its downstream target genes in regulating proliferation and growth of the CD133+ glioma cancer stem cells.
###end p 40
###begin p 41
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Prendergast1">[33]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Knezevic1">[50]</xref>
###xml 336 340 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Prendergast1">[33]</xref>
###xml 727 731 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Strasser1">[51]</xref>
###xml 740 744 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Jacobs1">[52]</xref>
###xml 785 789 785 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Eischen1">[53]</xref>
###xml 1147 1151 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Arvanitis1">[54]</xref>
###xml 1190 1194 1190 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Jain1">[55]</xref>
###xml 1211 1215 1211 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Flores1">[56]</xref>
###xml 1471 1475 1471 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Shachaf2">[57]</xref>
###xml 1737 1741 1737 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Boxer1">[58]</xref>
###xml 1743 1747 1743 1747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-DCruz1">[59]</xref>
###xml 1749 1753 1749 1753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Karlsson1">[60]</xref>
###xml 2091 2099 2091 2099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g004">Figure 4</xref>
###xml 2217 2225 2217 2225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003769-g006">Figure 6</xref>
###xml 2478 2482 2478 2482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Wang1">[61]</xref>
###xml 2484 2488 2484 2488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Wu1">[62]</xref>
###xml 2490 2494 2490 2494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Cappellen1">[63]</xref>
###xml 386 391 <span type="species:ncbi:9606">human</span>
###xml 608 613 <span type="species:ncbi:10090">mouse</span>
###xml 937 942 <span type="species:ncbi:10090">mouse</span>
###xml 2206 2215 <span type="species:ncbi:10090">nude mice</span>
Apoptosis can be induced by aberrant expression of certain oncogenes, such as c-Myc and E2F1, which may act as a "fail-safe" mechanism to eradicate potential cellular transformation [33], [50]. Apoptosis induced by c-Myc can be mediated through activation of the ARF-MDM2-p53 pathway, or by activating death receptors, such as CD95/Fas [33]. However, deregulation of c-Myc is common in human tumors and is an indicator of poor prognosis because tumors are well equipped with various anti-apoptosis mechanisms which can neutralize the apoptotic pressure introduced by c-Myc. Tumorigenesis in c-Myc transgenic mouse models is accelerated if combined with other anti-apoptosis genetic alterations, such as overexpression of Bcl-2 [51] or Bmi1 [52], or disrupting the ARF-MDM2-p53 pathway [53]. Further, it has been directly demonstrated that sustained c-Myc activity is required for tumor maintenance in a variety of conditional transgenic mouse models. These models show that inactivation of c-Myc almost inevitably results in tumor regression regardless of tumor type with concomitant growth inhibition, differentiation, and apoptosis (reviewed in [54]). In some cases, such as osteosarcoma [55] and skin tumors [56], brief inactivation of c-Myc is sufficient to induce sustained tumor regression. However, the dependence on c-Myc can be tumor-type specific. In certain conditional transgenic models, reactivation of c-Myc after transient disruption restores tumor growth [57], which may involve activation of dormant cancer stem cells. Alternatively, tumors may relapse in a portion of animals even in the absence of c-Myc activity, suggesting that cancer stem cells may have accumulated additional mutations to compensate loss of c-Myc [58], [59], [60]. The sustained tumor regression may be associated with complete eradication of cancer stem cells following inactivation of c-Myc, whereas cancer stem cells may survive and/or escape c-Myc dependence in recurrent tumors. Our study demonstrated a marked induction of apoptosis following c-Myc knockdown in the cancer stem cell population (Figure 4), and the cancer stem cells depleted of c-Myc expression failed to develop orthotopic xenograft tumors in nude mice (Figure 6). Of particular interest, survival of the non-stem glioma cells was not dependent on sustained expression of c-Myc. In a number of recent studies in other cancer models, targeting c-Myc expression impaired cellular proliferation and induced senescence [61], [62], [63]. These models may represent outcome of loss of c-Myc in more homogeneous cancer cell populations, particularly genetically engineered models driven by overexpression of c-Myc. Our study has important implications as targeting c-Myc has unique benefits specific to cellular compartments in models representing cellular heterogeneity. Although targeting c-Myc was sufficient to prevent tumor growth in our studies, the dichotomous effects of c-Myc inhibition that we have detected may support the need to simultaneously target the non-stem cell tumor populations to achieve clinical efficacy. Thus, c-Myc as a molecular target must be approached with sophistication as the majority of tumor cells may demonstrate limited therapeutic responses but a critical tumor population - the cancer stem cells - may be inhibited or killed to improve overall tumor control and decrease resistance to other therapies. Taken together, our study suggests that the proliferation, growth, and survival of glioma cancer stem cells are critically dependent on c-Myc expression and that targeting c-Myc pathways may significantly improve brain tumor therapy.
###end p 41
###begin title 42
Materials and Methods
###end title 42
###begin title 43
Cell isolation and culture
###end title 43
###begin p 44
###xml 467 470 467 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao1">[3]</xref>
###xml 472 475 472 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003769-Bao2">[9]</xref>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 311 318 <span type="species:ncbi:9606">patient</span>
###xml 398 403 <span type="species:ncbi:9606">human</span>
###xml 1166 1172 <span type="species:ncbi:9913">bovine</span>
###xml 1366 1371 <span type="species:ncbi:9606">human</span>
###xml 1470 1479 <span type="species:ncbi:10090">nude mice</span>
Primary glioma surgical biopsy specimens were obtained from patients undergoing resection for newly diagnosed or recurrent glioma in accordance with protocols approved by the Duke University Medical Center Institutional Review Board. Written consent to utilize excess tissue for research was obtained from each patient, and de-identified tissues were used for all studies. Cells were isolated from human glioma surgical specimens and cultured as previously described [3], [9]. Briefly, tumors were dissected, washed in Earle's balanced salt solution, digested with papain, titurated, and filtered. Red blood cells were lysed in diluted phosphate buffered saline solution (0.25x). Glioma cells were then cultured overnight in stem cell media (neurobasal media supplemented with B27 and epidermal growth factor and basic fibroblast growth factor (Invitrogen, Carlsbad, CA) at 20 ng/ml) prior to cell sorting for recovery of cellular surface antigens. The CD133- and CD133+ fractions were separated by magnetic sorting using the CD133 Microbead kit (Miltenyi Biotec, Auburn, CA). CD133- cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (Invitrogen), but were cultured in stem cell media at least 24 hours prior to experiments to control differences in cell media. T3359, T3832, T4302 and T4597 were originally derived from human glioma surgical biopsy specimens and were maintained as subcutaneous xenografts in athymic BALB/c nude mice.
###end p 44
###begin title 45
Antibodies
###end title 45
###begin p 46
###xml 140 141 140 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 470 479 470 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 37 42 <span type="species:ncbi:10090">Mouse</span>
###xml 87 93 <span type="species:ncbi:9986">rabbit</span>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
###xml 160 166 <span type="species:ncbi:9986">rabbit</span>
###xml 200 205 <span type="species:ncbi:10090">mouse</span>
###xml 237 242 <span type="species:ncbi:10090">mouse</span>
###xml 336 341 <span type="species:ncbi:10090">mouse</span>
###xml 391 395 <span type="species:ncbi:9925">goat</span>
###xml 456 461 <span type="species:ncbi:10090">mouse</span>
###xml 539 544 <span type="species:ncbi:10090">mouse</span>
The antibodies used were as follows: Mouse anti-c-Myc antibody (9E10), FITC-conjugated rabbit anti-c-Myc antibody (A14), mouse anti-cyclin D1 antibody (DCS-6), rabbit anti-cyclin D2 antibody (H-289), mouse anti-cyclin E antibody (13A3), mouse anti-p53 antibody (DO-1) were from Santa Cruz Biotechnology (Santa Cruz, CA); APC-conjugated mouse anti-CD133 antibody (AC133-1) was from Miltenyi; goat anti-Olig2 antibody was from R&D Systems (Minneapolis, MN); mouse anti-p21WAF1/CIP1 antibody was from Cell signaling Technology (Danvers, MA); mouse anti-actin antibody was from Millipore (Billerica, MA).
###end p 46
###begin title 47
Immunofluorescent staining
###end title 47
###begin p 48
###xml 1000 1001 994 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 400 404 <span type="species:ncbi:9925">goat</span>
###xml 894 899 <span type="species:ncbi:10090">mouse</span>
###xml 931 937 <span type="species:ncbi:9986">rabbit</span>
###xml 981 985 <span type="species:ncbi:9925">goat</span>
###xml 991 996 <span type="species:ncbi:10090">mouse</span>
###xml 1033 1037 <span type="species:ncbi:9925">goat</span>
###xml 1043 1049 <span type="species:ncbi:9986">rabbit</span>
Freshly frozen human glioma surgical biopsy samples were processed and 10 micron sections were mounted on glass slides in accordance with the Duke University Medical Center Institutional Review Board. Prior to staining, the sections were fixed in 4% paraformaldehyde at room temperature for 10 minutes, boiled in 10 mM sodium citrate solution (pH = 6.0) for 10 minute, and were blocked in 10% normal goat serum (Sigma-Aldrich, St. Louis, MO) and 0.1% Triton X-100 for 30 minutes at room temperature. Sections were incubated with primary antibodies at 4degreesC overnight and secondary antibodies at room temperature for 45 minutes, and then were counterstained with Hoechst 33342 (Invitrogen). For fluorescence imaging, confocal z-stacks were taken by a 63x water immersion objective lens on a Leica SP-5 microscope using sequential scans (blue-red, green). The following antibodies were used: mouse anti-c-Myc (Santa Cruz, 1:50), rabbit anti-Nestin (Abcam, Cambridge, MA, 1:100); goat anti-mouse IgG1 Alexa 488 (Invitrogen, 1:200), goat anti-rabbit IgG Alexa 568 (Invitrogen, 1:200).
###end p 48
###begin title 49
Lentivirus production
###end title 49
###begin p 50
The lentiviral vectors directing expression of shRNA specific to c-Myc (TRCN0000039640 and TRCN0000039641) or a non-targeting shRNA (SHC002) (Sigma-Aldrich) were co-transfected with the packaging vectors psPAX2 and pCI-VSVG (Addgene, Cambridge, MA) into 293FT cells by lipofectamine 2000 (Invitrogen) to produce virus. Two days following transfection, viral supernatants were collected, filtered, and concentrated by ultracentrifugation at 100,000 g for 3 hours.
###end p 50
###begin title 51
FACS analysis
###end title 51
###begin p 52
Glioma cells isolated from surgical biopsy specimens were fixed in 4% paraformaldehyde, and permeablized in 0.1% Triton X-100 for 10 minutes. Cells were then washed twice in PBS and labeled with APC-conjugated CD133 antibody (AC133, 1:11) and FITC-conjugated c-Myc antibody (A14, 1:50) for 1 hour at room temperate. Cells were then washed once in PBS and sorted.
###end p 52
###begin title 53
Real-time PCR
###end title 53
###begin p 54
###xml 401 402 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 585 611 579 605 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGAAAATCTGGCACCACACC-3&#8242;</named-content>
###xml 621 647 615 641 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGAGGCGTACAGGGATAGCA-3&#8242;</named-content>
###xml 664 694 658 688 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGACCTTGATTTATTTTGCATACC-3&#8242;</named-content>
###xml 704 730 698 724 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGAGCAAGACGTTCAGTCCT-3&#8242;</named-content>
###xml 747 773 741 767 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCAAGAGGCGAACACACAAC-3&#8242;</named-content>
###xml 783 809 777 803 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCCTTTTCATTGTTTTCCA-3&#8242;</named-content>
###xml 830 856 824 850 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCGCTGGCCATGAACTACCT-3&#8242;</named-content>
###xml 866 891 860 885 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACGAAGGTCTGCGCGTGTT-3&#8242;</named-content>
###xml 912 936 906 930 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGGAGCTGCTGTGCCACG-3&#8242;</named-content>
###xml 946 970 940 964 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTGGCCACCATTCTGCGC-3&#8242;</named-content>
###xml 975 984 969 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 994 1022 988 1016 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCACTGTCTTGTACCCTTGTGC-3&#8242;</named-content>
###xml 1032 1058 1026 1052 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCGTTTGGAGTGGTAGAAA-3&#8242;</named-content>
Total RNA was prepared using the RNeasy kit (Qiagen, Valencia, CA), and reverse transcribed into cDNA by iScript cDNA synthesis kit (BioRad, Hercules, CA). Real-time PCR was performed on an ABI 7900HT system using SYBR-Green Mastermix (SuperArray, Frederick, MD). PCR products were verified by melting curves and were also run on a 2% agarose gel to confirm the appropriate size. The threshold cycle (CT) values for each gene were normalized to expression levels of beta-Actin and HPRT1 (hypoxanthine phosphoribosyltransferase 1). The primers used were as follows: beta-Actin, forward 5'-AGAAAATCTGGCACCACACC-3'; reverse 5'-AGAGGCGTACAGGGATAGCA-3'; HPRT1, forward 5'-TGACCTTGATTTATTTTGCATACC-3'; reverse 5'-CGAGCAAGACGTTCAGTCCT-3'; c-Myc, forward 5'-TCAAGAGGCGAACACACAAC-3'; reverse 5'-GGCCTTTTCATTGTTTTCCA-3'; cyclin D1, forward 5'-CCGCTGGCCATGAACTACCT-3'; reverse 5'-ACGAAGGTCTGCGCGTGTT-3'; cyclin D2, forward 5'-TGGAGCTGCTGTGCCACG-3'; reverse 5'-GTGGCCACCATTCTGCGC-3'; p21WAF1/CIP1, forward 5'-TCACTGTCTTGTACCCTTGTGC-3'; reverse 5'-GGCGTTTGGAGTGGTAGAAA-3'.
###end p 54
###begin title 55
Growth Curve and Neurosphere formation assay
###end title 55
###begin p 56
Both CD133- and CD133+ glioma fractions of glioma cells were infected by the control lentivirus or lentivirus directing expression of c-Myc shRNA and were selected with 1 microg/ml puromycin for 2 days. 5000 CD133- cells or 1000 CD133+ cells were plated in 96-well plate in triplicate. Cell number was measured for 5 consecutive days using the CellTiter-Glo assay kit (Promega, Madison, MI). Additionally, 100 or 10 CD133+ cells were seeded per well in 24-well tissue culture plates. Eight wells were plated for each group. Seven days after plating, neurospheres containing more than 20 cells were scored.
###end p 56
###begin title 57
Intracranial xenograft formation assay
###end title 57
###begin p 58
###xml 143 152 <span type="species:ncbi:10090">nude mice</span>
###xml 240 244 <span type="species:ncbi:10090">Mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
5000 T3359 CD133+ cells lentivirally infected and selected for expression of the puromycin marker were implanted into brains of athymic BALB/c nude mice under a Duke University Institutional Animal Care and Use Committee-approved protocol. Mice were maintained for 100 days or until development of neurologic signs. Brains of euthanized mice were collected, fixed in 4% paraformaldehyde, paraffin embedded, sectioned, and subjected to hematoxylin and eosin staining.
###end p 58
###begin p 59
We thank Y. H. Sun, S. Keir, D. Satterfield, L. Ehinger and J. Faison for technical assistance. We are also grateful to R. Wechsler-Reya for helpful discussions.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
###xml 29 34 <span type="species:ncbi:9606">human</span>
Targeting of CD44 eradicates human acute myeloid leukemic stem cells.
###end article-title 61
###begin article-title 62
PML targeting eradicates quiescent leukaemia-initiating cells.
###end article-title 62
###begin article-title 63
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
###end article-title 63
###begin article-title 64
###xml 92 97 <span type="species:ncbi:9606">human</span>
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.
###end article-title 64
###begin article-title 65
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
###end article-title 65
###begin article-title 66
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.
###end article-title 66
###begin article-title 67
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
###end article-title 67
###begin article-title 68
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.
###end article-title 68
###begin article-title 69
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
###end article-title 69
###begin article-title 70
###xml 48 53 <span type="species:ncbi:9606">human</span>
The Myc oncoprotein as a therapeutic target for human cancer.
###end article-title 70
###begin article-title 71
More than just proliferation: Myc function in stem cells.
###end article-title 71
###begin article-title 72
Module map of stem cell genes guides creation of epithelial cancer stem cells.
###end article-title 72
###begin article-title 73
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.
###end article-title 73
###begin article-title 74
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
###xml 72 77 <span type="species:ncbi:9606">human</span>
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.
###end article-title 74
###begin article-title 75
Why myc? An unexpected ingredient in the stem cell cocktail.
###end article-title 75
###begin article-title 76
###xml 47 52 <span type="species:ncbi:9606">human</span>
Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
###end article-title 76
###begin article-title 77
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation.
###end article-title 77
###begin article-title 78
Deregulated expression of c-Myc depletes epidermal stem cells.
###end article-title 78
###begin article-title 79
###xml 34 39 <span type="species:ncbi:9606">human</span>
c-Myc promotes differentiation of human epidermal stem cells.
###end article-title 79
###begin article-title 80
Molecular pathology of malignant gliomas.
###end article-title 80
###begin article-title 81
c-myc oncogene family expression in glioblastoma and survival.
###end article-title 81
###begin article-title 82
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas.
###end article-title 82
###begin article-title 83
Targeting cancer stem cells through L1CAM suppresses glioma growth.
###end article-title 83
###begin article-title 84
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.
###end article-title 84
###begin article-title 85
Optimized flow cytometric analysis of central nervous system tissue reveals novel functional relationships among cells expressing CD133, CD15, and CD24.
###end article-title 85
###begin article-title 86
The c-Myc target gene network.
###end article-title 86
###begin article-title 87
Control of cell proliferation by Myc.
###end article-title 87
###begin article-title 88
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human brain tumour initiating cells.
###end article-title 88
###begin article-title 89
###xml 40 45 <span type="species:ncbi:9606">human</span>
Identification of a cancer stem cell in human brain tumors.
###end article-title 89
###begin article-title 90
Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis.
###end article-title 90
###begin article-title 91
The many roles of c-Myc in apoptosis.
###end article-title 91
###begin article-title 92
###xml 113 118 <span type="species:ncbi:9606">human</span>
A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
###end article-title 92
###begin article-title 93
Mechanisms of apoptosis by c-Myc.
###end article-title 93
###begin article-title 94
Strengths and limitations of the neurosphere culture system.
###end article-title 94
###begin article-title 95
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.
###end article-title 95
###begin article-title 96
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.
###end article-title 96
###begin article-title 97
Prospective identification of tumorigenic breast cancer cells.
###end article-title 97
###begin article-title 98
###xml 32 37 <span type="species:ncbi:9606">human</span>
Identification and expansion of human colon-cancer-initiating cells.
###end article-title 98
###begin article-title 99
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.
###end article-title 99
###begin article-title 100
Identification of pancreatic cancer stem cells.
###end article-title 100
###begin article-title 101
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
###end article-title 101
###begin article-title 102
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.
###end article-title 102
###begin article-title 103
Cancer stem cells: models and concepts.
###end article-title 103
###begin article-title 104
###xml 23 28 <span type="species:ncbi:9606">human</span>
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.
###end article-title 104
###begin article-title 105
Effects of RAS on the genesis of embryonal rhabdomyosarcoma.
###end article-title 105
###begin article-title 106
###xml 66 71 <span type="species:ncbi:9606">human</span>
Global mapping of c-Myc binding sites and target gene networks in human B cells.
###end article-title 106
###begin article-title 107
Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle.
###end article-title 107
###begin article-title 108
Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.
###end article-title 108
###begin article-title 109
###xml 139 144 <span type="species:ncbi:9606">human</span>
Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
###end article-title 109
###begin article-title 110
Role of E2F1 in apoptosis: a case study in feedback loops.
###end article-title 110
###begin article-title 111
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
###end article-title 111
###begin article-title 112
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
###end article-title 112
###begin article-title 113
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
###end article-title 113
###begin article-title 114
Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
###end article-title 114
###begin article-title 115
Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
###end article-title 115
###begin article-title 116
Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia.
###end article-title 116
###begin article-title 117
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
###end article-title 117
###begin article-title 118
Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.
###end article-title 118
###begin article-title 119
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
###end article-title 119
###begin article-title 120
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations.
###end article-title 120
###begin article-title 121
###xml 42 47 <span type="species:ncbi:9606">human</span>
c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.
###end article-title 121
###begin article-title 122
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.
###end article-title 122
###begin article-title 123
Novel c-MYC target genes mediate differential effects on cell proliferation and migration.
###end article-title 123
###begin p 124
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 124
###begin p 125
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Jialiang Wang is a recipient of the American Brain Tumor Association Basic Research Fellowship. Other financial support was provided by the Childhood Brain Tumor Foundation, the Pediatric Brain Tumor Foundation of the United States, Accelerate Brain Cancer Cure, Alexander and Margaret Stewart Trust, Brain Tumor Society, Goldhirsh Foundation, Duke Comprehensive Cancer Center Stem Cell Initiative Grant (J.R.), NIH grants NS047409, NS054276, and CA116659 (J.R.). J.R. is a Damon Runyon-Lilly Clinical Investigator supported by the Damon Runyon Cancer Research Foundation and a Sidney Kimmel Foundation for Cancer Research Scholar. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 125

